I would rather just use Recaf.

Ovarian cancer is a difficult cancer to diagnose, many of the symptoms are confounding and can be related to other illnesses (bloating, abdominal pain, frequent urination, etc.), thus delaying the diagnosis further. In some women a pelvic mass is identified which is then evaluated for an ovarian malignancy. There are approximately 250,000 women who present each year to their physician with an undiagnosed pelvic mass, 20% of which will be diagnosed, following evaluation, with malignant ovarian cancer. The CA 125 test is not recommended for use to diagnose patients with suspected ovarian cancer as there are other benign conditions that can affect the CA 125 value.

CA 15-3® and CA27.29 are biomarkers that are highly associated with breast cancer and are derived from the MUC1 gene. Neither of these markers is recommended by physician organizations for use in the screening or detection of breast cancer. This is in part due to the elevation of the markers in benign conditions including: breast, liver and kidney disorders and other cancers.

CA 19-9® is a test that measures proteins shed by pancreatic cancer cells. The test is used as an aid in monitoring disease status in those patients having confirmed pancreatic cancer who have levels of serum or plasma CA 19-9 above the cutoff, at the time of diagnosis. The biomarker CA 19-9 can be elevated in other cancers and benign conditions such as colorectal cancer, pancreatitis, liver disease, as well as others.

http://fdi.com/us_home/patients/ovar...